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Abstract : The aim of this study was to
design a simple method for detecting the
amyloid A4 protein in the cerebrospinal fluid
(CSF) of patients who had severe brain
trauma caused by traffic or other accidents
and to evaluate its diagnostic and prognostic
value. For this purpose, a sandwich type
ELISA assay was used. A4, a 4kDa protein of
39-43 amino acids, is a metabolic product of
a membrane-spanning, 695-770 aa,
precursor molecule, the β-amyloid precursor
protein (β-APP). The polyclonal rabbit
antibody against synthetic A4 protein (1-40
residues) was used as an immobilized
antibody. A mouse monoclonal antibody
against synthetic A4 protein (1-28 residues)
was used as a different immunoglobulin to
attach the A4. Enzyme-labelled antiimmunoglobulin (peroxidase rabbit antimouse antibody, PRAM) was used for reaction
with mouse immunoglobulin. The assay was
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Introduction
A4, a 4kDa protein of 39-43 amino acids, is a
metabolic product of a membrane-spanning, 695-770
amino acid, precursor molecule, the β-amyloid precursor
protein (β-APP). Amyloid precursor protein 695-770 aa
(β-APP), is a transmembrane protein which is encoded
by a gene on chromosome 21 and is constitutively
secreted by both brain and non-brain cells into
extracellular fluids throughout life (1,2). Intensive
investigations have focused on the metabolic
mechanisms generating A4 (3,4). APP can be
metabolically processed by at least two pathways. The
α-secretase pathway cleaves β-APP in the central section
of the A4 domain (5,6) and thereby precludes
amyloidogenesis, whereas the β-secretase pathway
generates the free N-terminus of intact A4 (7). It is now
widely accepted that the deposition of the A4 within the
brain parenchyma and in cerebromeningeal blood vessels

highly specific for A4, demonstrating no cross
reactivity between polyclonal anti A4 and
monoclonal A4 antibodies (<0.7% cross
reactivity). The lowest detectable value in the
assay was 100ng/ml (1ng/well). Our results
showed that, in CSF samples of 30 patients
with head trauma caused by traffic or other
accidents and 14 controls drawn from
children and adults who presented with acute
headache or meningeal irritation and were
tested by ELISA for A4 protein, only the CSF
samples of patients with head trauma
displayed elevated A4 reactivity. This assay
thus permits the detection of abnormal
fragments of β-APP (A4) within the CSF. It
means that severe head trauma may cause
abnormal production of A4 which leads to
amyloid deposition and, in turn, neuronal
degeneration.
Key Words: Beta-Amyloid protein (A4), Head
Trauma, ELISA

is an early and necessary feature of Alzheimer’s disease,
which is the most common cause of age-related mental
failure (8-10). The relationship between head trauma
and the immediate production of A4, in turn diffusing
into CSF, is not clear, since A4 production and
accumulation in the brain take years. It is, however,
likely that severe head trauma leads to the production of
A4, which passes into CSF.
The aim of this work was to measure the abnormal
fragment of amyloid precursor protein A4 within the CSF
in the case of head trauma using a sandwich-ELISA
method. Here, we report A4 appearance in the CSF
samples of patients who had severe head trauma.
The aim of this study was to design a simple method
for detecting the A4 protein within CSF samples from
patients who had brain trauma, and to evaluate its
diagnostic and prognostic value. For this purpose, a
sandwich type ELISA assay was used.
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Materials and Methods
Patients and control:
All patients (21 male 43±21; 9 female, 41±22) who
had head trauma were investigated for intracranial
hemorrhage. The controls (9 male, 26±22; 5 female,
33±24) were drawn from children and adults who
presented with acute headache or meningeal irritation
and who had a lumbar puncture performed for
investigation of suspected meningitis.
Specimen Collection and Analysis
CSF was obtained by lumbar puncture under sterile
conditions. Blood-stained CSF samples were centrifuged
promptly. The CSFs were stored at 4ºC for no longer
than 4 days.
Specimen collection (including sample volume) was
dictated solely by clinical considerations and no additional
specimens were collected for the purposes of this study.
Reagents
Synthetic A4 peptide fragment (1-40) of β-APP,
polyclonal anti-A4(1-40) antibody and peroxidaseconjugated rabbit immunoglobulins to mouse
immunoglobulins (PRAM) were obtained from Sigma
(A1075, A8326 and A9044 respectively). Monoclonal
anti A4-antibody (1-28) was kindly provided by Dr. M.
Landon, Nottingham Univ., Biochem. Dept., England.
Assay
In preparation for the assay, 96-well Maxisorp plates
(Cat. no.469949; Nunc Roskilde, Denmark) were
passively coated at 37ºC for 24 h with polyclonal anti-A4
antibody (200µl/well). After five washes with washing
buffer (distilled water containing 0.5ml/l Tween 20),
100µl of different concentrations of synthetic A4 (1-40
peptide), (concentration range 10, 30, 50, 70, 90, 100
ng/well) and CSF of the patients (neat) were added to the
wells. Then, 100µl mouse monoclonal anti A4 antibody
(1:1000 dilution) was added to each well. We then added
100µl of peroxidase-labelled anti-mouse immunoglobulin
antibody (dilution of 1:500) to each well. After 4h
incubation and 10 washes with 300µl of washing buffer
per well, to each well we added 200µl of substrate
solution
(0.1%w/w
ABTS
(2,2azino-bis,
3ethylbenzthiazoline-6-sulphonic acid), 0.003%v/v H2O2
(100 vol) in citrate/phosphate buffer pH4). After
incubation for 15 min, the reaction was terminated by
0.1 M citric acid. The absorbance of the plates was read
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at 405 nm with a spectrophotometer. The colour change
was proportional to the amount of antigen in the test
solution.

Results
Plates passively coated with polyclonal anti-A4
antibody were used for the CSF samples of the patient
and control groups. In addition, in order to draw a
standard curve, different synthetically produced A4
peptide (A1075 Sigma) concentrations were prepared
(50µg/ml, 10µg/ml, 1µg/ml, 0.1µg/ml, 0.01µg/ml and
0.001µg/ml) and constant monoclonal anti-A4 peptide
antibody was used (1:1000 dilution). The interassay
reproducibility (expressed in µg/ml) was examined with
A4 standard samples of the dilution curve. The interassay
variation was monitored by running the assay three
times. The detectable value of the assay was 1ng/well for
synthetic peptide. The lower limit of the assay always
present problems in ELISA. In our study, we used a lower
limit of 1.5 times the background value.
The background was defined in two ways: either from
a well containing all reagents except the sample, or from
a well containing a known negative sample. The graph for
absorbance versus the amount of A4 peptide was drawn
(Figure 1). The A4 peptide concentrations in the CSF of
the samples were determined with a standard A4 peptide
concentration curve. The control and patient groups were
sorted according to age groups (Table 1). The graph for
the patient and control groups versus A4 peptide
concentration was drawn (Figure 2).
When patients with head trauma were compared to
the control group, increased A4 concentrations were
determined in patients with head trauma. Older patients
with trauma showed higher concentrations than both
younger patients with trauma and the control group.

Discussion
In this sandwich-type enzyme immunoassay for β-A4
protein, antibody is labelled with classical peroxidase
(Sigma, PRAM). The peroxidase-labelled Fab fragment of
antibody is directed against monoclonal antibody which is
against the 1-28 residues of the β-A4 fragment and the
immobilised polyclonal antibody coated onto the surface
of the wells of 96-well plates is directed against the 1-40
residues of β-A4. This sandwich-type enzyme
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Figure 1.

Passively polyclonal anti-A4 antibody-coated ELISA plates
were used for different concentrations of synthetic A4
peptide (1-40 amino acid residues of APP). Monoclonal
anti-A4 antibody was then used. The sandwich-ELISA
complex was identified by enzyme-labelled anti-mouse
immunoglobulins.

Table 1.

Patients and control group sorted according to age. Each group is listed alphabetically. Arithmetic means and SD of A4 absorbance values
of CSF are given for each group. Concentration of A4 within CSF was calculated from the standard curve (Fig.1).

AGE GROUPS

0-9
10-19
20-29
30-39
40-49
50-59
60-69

Figure 2.
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Polyclonal anti-A4 antibody coated ELISA plates were used
for CSF samples of head trauma and control groups.
Monoclonal anti-A4 antibody was than added. The
sandwich-ELISA complex was identified by enzymelabelled anti-mouse immunoglobulins. The graph was
drawn according to the concentration values in Table 1.

Head Trauma, CSF A4 Absorbance and
Corresponding Concentration (ng/ml)
A
B
C
D
E
F
G

(n:3)
(n:3)
(n:4)
(n:3)
(n:3)
(n:7)
(n:7)

0.290±0.02
0.373±0.15
0.354±0.17
0.369±0.14
0.544±0.19
0.625±0.18
0.777±0.34

1.8±0.06
2.8±0.09
2.3±0.1
2.6±0.27
11.8±2.08
21±3.67
60.1±8.97

ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml
ng/ml

Control, CSF A4 Absorbance and
Corresponding Concentration (ng/ml)
(n:4)
(n:3)
(n:1)
(n:1)
(n:2)
(n:1)
(n:2)

0.133±0.02
0.115±0.01
0.199
0.219
0.270±0.1
0.279
0.332±0.13

*
*
*
*
*
2.1 ng/ml
2.2±0.04 ng/ml

* Values were below or at the cut-off ELISA absorbance range

immunoassay is quite sensitive, detecting 1ng β-A4 per
well. The method is also specific, the cross-reactivity
found with PRAM and immobilised polyclonal antibody
being either undetectable or very small. The intra- and
interassay reproducibility tests carried out with standard
samples of A4 peptide gave results in the range of values
which we obtained.
This study of 14 control subjects of both sexes
between the ages of 7 and 62 allowed us to show a very
low level of absorbance at 405 nm which was not
significant for ELISA detection. However, the CSF

samples of the head-trauma patients exhibited increasing
concentrations of A4 together with age, time of LP
(lumbar puncture) and severity of trauma. The earliestperformed LP in the patients was 5 h after the accident
occurred. The relationship between traumatic brain injury
and the precocious development of neurodegenerative
cascades, including diffuse deposits of β-A4 proteins in
the injured brain and the leaking of it in CSF, will enable
the design of a diagnostic test for brain-cell degeneration.
At present, no diagnostic technique for Alzheimer’s
disease, motor neurone disease or similar
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neurodegenerative disease exists for patients except at
postmortem. Neuronal cell death is a very important
factor in all these diseases and in severe head trauma,
involving the deposition of β-A4 protein. It has been
postulated that on the death and subsequent lysis of these
cells, the previous constituents of the cells, including the
β-A4 protein, will leak out into the CSF and serum. Thus,
if it were possible to detect the β-A4 protein in a sample
of CSF taken from a living patient suspected of having a
neurodegenerative disease or severe neuronal damage, an
accurate diagnosis could be reached while the patient was
still alive.
It has been shown that A4 peptide can be detected
immunocytochemically at sites of axonal injury in the
brain. It was recently found to be a useful marker for

injured axons in patients who survived for only 3h after
head trauma (11). β-A4 immunocytochemistry may be
useful in the detection of traumatic axonal injury in its
early stages (12).
Animal experiments have revealed similar results. In
one study, rats were subjected to brain injury. At 1h, 2h,
48h, 1 week or 2 weeks after injury, the animals were
killed
and
their
brains
were
analysed
immunohistochemically. β-A4 immunoreactivity increased
as early as 1h after injury and persisted for at least 2
weeks (13).
In conclusion, by using the Sandwich-type ELISA
method described in this study, it is possible to measure
the A4 level within CSF, and it may indicate the extent of
neuronal degeneration caused by trauma.
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